natgillin/translations-raw huggingface dataset:
It is used in combination with surgery and radiotherapy to reduce the risk of and delay the tumour coming back.
Uporablja se v kombinaciji s kirurškim posegom in radioterapijo za zmanjšanje nevarnosti ponovnega pojava bolezni in podaljšanje časa do ponovnega pojava bolezni.
A course of treatment consists of six doses of 1 ml, the first four given at intervals of one week, and the last two at two-week intervals.
Zdravljenje je sestavljeno iz šestih odmerkov po 1 ml, pri čemer se prve štiri injicira v enotedenskih presledkih, zadnja dva pa v razmiku dveh tednov.
Side effects that may be seen with Oncept IL-2 treatment are short lived apathy (lack of responsiveness) and hyperthermia (increased body temperature above 39.5 °C from the normal value of 38 - 38.5 °C).
Neželena učinka, ki se lahko pojavita pri uporabi zdravila Oncept IL-2, sta prehodna apatija (zmanjšana odzivnost) in hipertermija (povišana telesna temperatura nad 39,5 °C ob normalni vrednosti med 38 in 38,5 °C).
The studies showed that in cats treated with Oncept IL-2 the tumours took longer to come back (over 730 days based on the mid value of the range) compared with control cats (287 days).
Študije so pokazale, da so se pri mačkah, zdravljenih z zdravilom Oncept IL-2, tumorji ponovno pojavili kasneje (po več kot 730 dneh glede na srednjo vrednost razpona) kot pri mačkah v kontrolni skupini (po 287 dneh).
Treatment with Oncept IL-2 should begin the day before radiotherapy and preferably within one month of the removal of the tumour by surgery.
Zdravljenje z zdravilom Oncept IL-2 je treba začeti en dan pred radioterapijo in po možnosti v enem mesecu po kirurški odstranitvi tumorja.
It is available as a lyophilisate (freeze dried pellet) and solvent (water for injections) that are made up into a suspension for injection.
Na voljo je v obliki liofilizata (pelete, posušene v zamrznjenem stanju) in vehikla (vode za injekcije), iz katerih se pripravi suspenzija za injiciranje.
The benefit/risk balance may be found in the scientific discussion module of this EPAR.
Za razmerje med koristmi in tveganji glejte modul o znanstveni razpravi v tem povzetku.
Oncept IL-2 is used when the size of the tumour is between 2 and 5 cm in diameter and there is no spread of the cancer to other parts of the body.
Zdravilo Oncept IL-2 se uporablja, kadar je premer tumorja od 2 do 5 cm in se rak ni razširil na druge dele telesa.
The European Commission granted a marketing authorisation valid throughout the European Union, for Onept IL-2 on 3/05/2013.
Evropska komisija je dovoljenje za promet z zdravilom Oncept IL-2, veljavno po vsej Evropski uniji, odobrila dne 3. maja 2013.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Oncept IL-2 exceed the risks for the approved indication and recommended that Oncept IL-2 be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Oncept IL-2 za odobreno indikacijo večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Oncept-IL2 is an immunomodulating agent, which means that it affects the activity of the immune system (the body's natural defences).
Zdravilo Oncept IL-2 je imunomodulator, kar pomeni, da vpliva na delovanje imunskega sistema (naravnega obrambnega mehanizma telesa).
This is expected to kill the cancer cells.
S tem naj bi uničil rakave celice.
The two studies compared a total of 48 cats treated with Oncept IL-2 with 23 control cats that just received surgery and radiotherapy.
V študijah so skupno 48 mačk, zdravljenih z zdravilom Oncept IL-2, primerjali s 23 mačkami v kontrolni skupini, ki so tik pred tem prestale kirurški poseg in radioterapijo.
IL-2 works by stimulating some of the specialised cells of the immune system to attack the cancer cells.
IL2 deluje tako, da spodbuja nekatere posebne celice imunskega sistema k napadanju rakavih celic.
Oncept IL-2 was studied in two field studies involving 71 cats which had spontaneously developed fibrosarcoma that had not spread to other parts of the body.
Zdravilo Oncept IL-2 so raziskali v dveh terenskih študijah, ki sta vključevali 71 mačk, pri katerih se je spontano razvil fibrosarkom, ki se ni razširil na druge dele telesa.
If the product is accidentally self-injected, medical advice should be sought immediately and the package leaflet or label shown to the doctor.
V primeru nenamernega zaužitja zdravila se je treba takoj posvetovati z zdravnikom in mu pokazati navodila za uporabo ali ovojnino.
Other information about Oncept IL-2:
Druge informacije o zdravilu Oncept IL-2:
Oncept IL-2 is used to treat cats with fibrosarcoma, a type of aggressive tumour which affects the soft tissues.
Zdravilo Oncept IL-2 se uporablja za zdravljenje mačk s fibrosarkomom, tj. vrsto agresivnega tumorja, ki prizadene mehka tkiva.
What benefit has Oncept IL-2 shown during the studies?
Kakšne koristi je zdravilo Oncept IL-2 izkazalo med študijami?
Oncept-IL2 is produced by a method known as ‘recombinant DNA technology': it contains viruses that have received a gene (DNA), which makes them able to produce IL-2.
Zdravilo Oncept IL-2 se proizvaja z metodo, znano kot „tehnologija rekombinantne DNK‟, pri kateri virusi prejmejo gen (DNK), s katerim lahko tvorijo IL-2.
The virus allows the production of IL-2 in small amounts and for a prolonged time at the injection site.
Virus omogoča, da se na mestu injiciranja daljši čas tvorijo majhne količine IL-2.
What is the risk associated with Oncept IL-2?
Kakšna tveganja so povezana z zdravilom Oncept IL-2?
Oncept IL-2 is a veterinary medicine that contains the active substance feline interleukin-2 recombinant canarypox virus (vCP1338).
Oncept IL-2 je zdravilo za uporabo v veterinarski medicini, ki vsebuje zdravilno učinkovino rekombinantni pox virus kanarčkov, ki vsebuje mačji interlevkin-2 (vCP1338).
Why has Oncept IL-2 been approved?
Zakaj je bilo zdravilo Oncept IL-2 odobreno?
The active substance in Oncept IL-2 is a ‘carrier' canarypox virus that contains the gene to produce the protein feline interleukin-2 (IL-2).
Zdravilna učinkovina v zdravilu Oncept IL-2 je „nosilni‟ pox virus kanarčkov, ki vsebuje gen za tvorjenje beljakovine, imenovane mačji interlevkin-2 (IL-2).
How has Oncept IL-2 been studied?
Kako je bilo zdravilo Oncept IL-2 raziskano?
Feline interleukin-2 recombinant canary pox virus
rekombinantni pox virus kanarčkov, ki vsebuje mačji interlevkin-2
What is Oncept IL-2 used for?
Za kaj se zdravilo Oncept IL-2 uporablja?
What is Oncept IL-2?
Kaj je zdravilo Oncept IL-2?
How does Oncept IL-2 work?
Kako zdravilo Oncept IL-2 deluje?
Avenida Río de Janeiro, 60 - 66, planta 13 08016 Barcelona (España)
Avenida Río de Janeiro, 60 - 66, planta 13 08016 Barcelona (Španija)
VIAL/MULTI PACKAGE
VIALA / VEČ-PAKETNI
The elimination half-life (t½) is 40-50 minutes.
Razpolovni čas izločanja (t½) je 40-50 minut.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES 1 ml contains:
NAVEDBA ZDRAVILNE UČINKOVINE IN DRUGIH SNOVI 1 ml vsebuje:
Spontaneous recovery occurs within 3 hours.
Do spontanega prenehanja delovanja pride v 3 urah.
After treatment, the animal should not be given water or food before it is able to swallow.
Po zdravljenju se živalim, dokler ne morejo požirati, ne daje vode ali hrane.
In a clinical study, the requirement for propofol was reduced by 50%.
V klinični študiji je bila potreba po propofolu zmanjšana za 50%.
Shelf life after first opening: 3 months at 25°C.
Rok trajanja po prvem odpiranju: 3 mesece pri 25°C.
In case of skin or mucosal contact, wash the exposed skin immediately after exposure with large amounts of water and remove contaminated clothes that are in direct contact with skin.
V primeru stika s kožo ali sluznico izpostavljen del nemudoma sperite z velikimi količinami vode in odstranite umazana oblačila, ki so v neposrednem stiku s kožo.
EXPIRY DATE EXP: month/year
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA EXP: mesec/leto
The mean half-life of elimination of dexmedetomidine increased to 1.6 h and the total exposure (AUC) increased by 50%.
Srednja vrednost razpolovnega časa izločanja deksmedetomidina se je povečala na 1,6 h, skupna izpostavljenost (AUC) pa za 50%.
However this duration is dependent on a number of variables and further analgesia should be administered in accordance with clinical judgement.
Njeno trajanje je odvisno od številnih dejavnikov, zato je treba nadaljnjo analgezijo dajati glede na klinično presojo.
The bioavailability of dexmedetomidine is 60% and the apparent volume of distribution (Vd) is 0.9 L/kg.
Biološka razpoložljivost deksmedetomidina je 60-odstotna in navidezni volumen porazdelitve (Vd) je 0,9 L/kg.
The administration of dexmedetomidine to puppies younger than 16 weeks and kittens younger than 12 weeks has not been studied.
Uporaba deksmedetomidina pri kužkih mlajših od 16 tednov in mačkah mlajših od 12 tednov ni bila preučena.
Respiratory and haemodynamic symptoms should be treated symptomatically.
Dihalne in hemodinamične simptome je potrebno zdraviti simptomatično.
ADVICE ON CORRECT ADMINISTRATION It is recommended that animals are fasted for 12 hours prior to administration.
NASVET O PRAVILNI UPORABI ZDRAVILA Priporočeno je, da živali postijo 12 ur pred uporabo zdravila.
Do not use after the expiry date stated on the label and carton after EXP.
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenem na nalepki in škatli po EXP.
The Marketing Authorisation Holder must ensure that the system of pharmacovigilance, as described in Part 1 of the marketing authorisation application, is in place and functioning before and whilst the veterinary medicinal product is on the market.
Imetnik dovoljenja za promet mora zagotoviti, da je sistem farmakovigilance, kot je opisan v delu I vloge za pridobitev dovoljenja za promet, vzpostavljen in deluje, preden da zdravilo v promet in ves čas trženja zdravila.
For information on target animal safety in cases of overdosing, see section 4.10.Overdose
Za informacije o varnosti v primeru prevelikega odmerjanja pri ciljnih živalih glejte 4.10, Preveliko odmerjanje.
Metabolites are excreted mainly in the urine (51% of the dose), and to a lesser extent in the faeces.
Presnovki se izločajo večinoma z urinom (51% odmerka) in v manjši meri z blatom.
Dexdomitor is compatible with butorphanol and ketamine in the same syringe at least for two hours.
Dexdomitor je združljiv z butorfanolom in ketaminom v isti brizgi najmanj dve uri.
After withdrawal of the first dose, the product may be stored for 3 months at 25ºC.
Po uporabi prvega odmerka zdravilo lahko hranite 3 mesece pri 25°C.
Do not use in case of known hypersensitivity to the active substance or to any of the excipients.
Ne uporabite v primeru preobčutljivosti za zdravilno učinkovino ali katerokoli pomožno snov.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS/ MULTI PACKAGE
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH / VEČ-PAKETNI
The apparent volume of distribution (Vd) is 2.2 L/kg and the elimination half-life (t½) is one hour.
Navidezni volumen porazdelitve (Vd) je 2,2 L/kg, razpolovni čas izločanja (t½) pa ena ura.
The product is intended for:
To zdravilo je namenjeno:
Persons with known hypersensitivity to the active substance or any of the excipients should administer the product with caution.
Osebe z znano preobčutljivostjo na zdravilno učinkovino ali katerokoli pomožno snov morajo previdno uporabljati zdravilo.
The product is not intended for repeat injections.
Zdravilo ni namenjeno za večkratno uporabo.
In case of accidental oral intake or self-injection, seek medical advice immediately and show the package insert to the physician but DO NOT DRIVE as sedation and changes in blood pressure may occur.
V primeru peroralnega zaužitja ali samoinjiciranja nemudoma poiščite zdravniško pomoč in zdravniku pokažite nalepko na ovojnini, vendar NE VOZITE, saj lahko pride do sedacije in sprememb v krvnem pritisku.
In cases of overdosing the following recommendations should be followed:
V primerih prevelikega odmerjanja upoštevajte naslednja navodila:
SPECIAL STORAGE PRECAUTIONS Do not freeze.
POSEBNA NAVODILA ZA SHRANJEVANJE Zdravilo ne sme zmrzniti.
Cats: The maximum plasma concentration is reached about 0.24 h after intramuscular administration.
Mačke: Najvišja koncentracija v plazmi je dosežena približno 0,24 ure po intramuskularni uporabi.
The eyes should be protected by a suitable lubricant.
Oči morate zaščititi z ustreznim mazilom.
Within 15 minutes dogs and cats are normally awake and standing.
Psi in mačke so ponavadi budni in stojijo po 15 minutah.
Sedation lasts for at least 120 minutes post administration and analgesia lasts for at least 90 minutes.
Sedacija traja vsaj 120 minut, analgezija pa vsaj 90 minut po uporabi.
Dog Weight
Psi Teža
The premedication dose of dexmedetomidine is 125 - 375 micrograms/square metre body surface area, administered 20 minutes prior to induction for procedures requiring anaesthesia.
Odmerek deksmedetomidina za pripravo na kirurški poseg je 125-375 mikrogramov/kvadratni meter telesne površine, dati pa ga je treba 20 minut pred začetkom postopka, za katerega je anestezija potrebna.
Administration of atipamezole after dexmedetomidine rapidly reverses the effects and thus shortens the recovery period.
Uporaba atipamezola po deksmedetomidinu hitro obrne učinke in tako skrajša obdobje prenehanja delovanja.
At high serum concentrations of dexmedetomidine sedation is not increased although the level of analgesia does increase with further dose increases.
Pri visokih serumskih koncentracijah deksmedetomidina se sedacija ne okrepi, vendar pa se s povečanjem odmerka povečuje raven analgezije.
Cat Weight
Mačke Teža
Major biotransformations in the dog include hydroxylation, glucuronic acid conjugation and Nmethylation in the liver.
Med večje biološke transformacije pri psih sodijo hidroksilacija, konjugacija glukuronske kisline in Nmetilacija v jetrih.
Therefore the use of the product during pregnancy and lactation is not recommended.
Zato uporaba v obdobju brejosti in laktacije ni priporočljiva.
In a clinical study, the requirement for propofol and thiopental was reduced by 30% and 60% respectively.
V klinični študiji je bila potreba po propofolu zmanjšana za 30 %, po tiopentalu pa za 60 %.
Pharmacotherapeutic group: psycholeptic, ATCvet code: QN05CM18.
Farmakoterapevtska skupina: psiholeptik, oznaka ATCvet: QN05CM18.
Dosage: the following doses are recommended:
Odmerek: priporočeni so naslednji odmerki:
Anticholinergics should be used with caution with dexmedetomidine.
Protiholinergične snovi morate skupaj z deksmedetomidinom uporabljati previdno.
Premedication in dogs and cats before induction and maintenance of general anaesthesia.
Priprava psov in mačk pred uvajanjem in vzdrževanjem splošne anestezije.
Dexdomitor, butorphanol and/or ketamine can be mixed in the same syringe as they have been shown to be pharmaceutically compatible.
Dexdomitor, butorfanol in/ali ketamin lahko zmešate v isti brizgi, saj so dokazano farmacevtsko združljivi.
PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: psycholeptic, ATCvet code: QN05CM18.
FARMAKOLOŠKE LASTNOSTI Farmakoterapevtska skupina: psiholeptik, oznaka ATCvet: QN05CM18.
Non-invasive, mildly to moderately painful, procedures and examinations which require restraint, sedation and analgesia in dogs and cats.
Neinvazivni, blago do zmerno boleči postopki in pregledi psov in mačk, pri katerih so potrebni mirovanje, sedacija in analgezija.
Treated animals should be kept warm and at a constant temperature, both during the procedure and recovery.
Živalim, zdravljenim s tem zdravilom, je potrebno tako med posegom in med okrevanjem zagotoviti, da so na toplem, pri konstantni temperaturi.
The specific α2-adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.
Specifičen antagonist α2 adrenoreceptorjev, odobren za uporabo pri malih živalih, je bil pri človeku uporabljen kot antagonist učinkov deksmedetomidina samo poskusno.
Sick and debilitated dogs and cats should only be premedicated with dexmedetomidine before induction and maintenance of general anaesthesia based on a risk-benefit assessment.
Bolne ali oslabljene pse in mačke smete pripraviti na poseg z deksmedetomidinom pred uvajanjem in vzdrževanjem splošne anestezije šele po oceni koristi in tveganja postopka.
If pregnant women handle the product, special caution should be observed not to self-inject as uterine contractions and decreased foetal blood pressure may occur after accidental systemic exposure.
Če zdravilo uporabljajo noseče ženske, je potrebno posebno paziti, da ne pride do samoinjiciranja, saj lahko po naključnem sistemskem izpostavljanju pride do materničnih popadkov in zmanjšanja krvnega pritiska ploda.
Advice to doctors: Dexdomitor is an α2-adrenoreceptor agonist, symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia.
Nasvet zdravnikom: Dexdomitor je agonist α2-adrenoreceptorjev, simptomi po absorpciji lahko vključujejo klinične učinke, vključno s sedacijo (odvisno od odmerka), dihalnim zastojem, bradikardijo, hipotenzijo, suhimi usti in hiperglikemijo.
When administering in conjunction with butorphanol (0.1 mg/kg) for deep sedation and analgesia, the intramuscular dose of dexmedetomidine is 300 micrograms/square metre body surface area.
Pri skupni uporabi z butorfanolom (0,1 mg/kg) za globoko sedacijo in analgezijo je intramuskularni odmerek deksmedetomidina 300 mikrogramov/kvadratni meter telesne površine.
The use of other central nervous system depressants is expected to potentiate the effects of dexmedetomidine and therefore an appropriate dose adjustment should be made.
Uporaba zaviralcev osrednjega živčevja okrepi učinke deksmedetomidina, zato je treba odmerek ustrezno prilagoditi.
Dexmedetomidine doses are based on body surface area:
Odmerki deksmedetomidina temeljijo na telesni površini.
PHARMACEUTICAL FORM Solution for injection Clear, colourless solution
FARMACEVTSKA OBLIKA Raztopina za injiciranje Bistra, brezbarvna raztopina
It is recommended that animals are fasted for 12 hours prior to Dexdomitor administration.
Priporočeno je postenje živali 12 ur pred dajanjem Dexdomitorja.
Sedation may be reversed with atipamezole.
Učinki sedacije se lahko izničijo z atipamezolom.
In some dogs and cats a decrease in respiratory rate may occur.
Pri nekaterih psih in mačkah se lahko zmanjša hitrost dihanja.
For information on adverse reactions, see section 4.6.Adverse reactions.
Za dodatne informacije o neželenih učinkih glejte 4.6, Neželeni učinki.
These may include profound sinus bradycardia, 1st and 2nd degree AV block, sinus arrest or pause, as well as atrial, supraventricular and ventricular premature complexes.
Mednje lahko sodijo globoka sinusna bradikardija, AV-blok prve in druge stopnje, sinusni zastoj ali prekinitev, prav tako prezgodnji preddvorni, nadprekatni in prekatni kompleksi.
When dexmedetomidine is used for premedication in cats, the same dose is used.
Pri uporabi deksmedetomidina za pripravo mačk na operacijo se uporablja isti odmerek.
4.7 Use during pregnancy or lactation
Uporaba v obdobju brejosti ali laktacije
Dexdomitor contains dexmedetomidine as the active substance, which produces sedation and analgesia in dogs and cats.
Dexdomitor kot zdravilno učinkovino vsebuje deksmedetomidin, ki pri psih in mačkah deluje kot sedativ in analgetik.
Concomitant use of dexmedetomidine and butorphanol produces sedative and analgesic effects beginning no later than 15 minutes.
Sočasna uporaba deksmedetomidina in butorfanola sproži sedativne in analgetične učinke v manj kot 15 minutah.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Active substance:
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGEIH SESTAVIN Zdravilna učinkovina:
After concurrent exposure to a triple (3X) overdose of dexmedetomidine and 15 mg ketamine/ kg, atipamezole can be administered at the recommended dose level for reversal of effects induced by dexmedetomidine.
Po zaporedni izpostavitvi trojnemu (3-kratnemu) odmerku deksmedetomidina in 15 mg ketamina/kg lahko za preobrat učinkov deksmedetomidina uporabite atipamezol v priporočenem odmerku.
TARGET SPECIES Dogs and cats
CILJNE ŽIVALSKE VRSTE Psi in mačke
Use of dexmedetomidine as a premedicant in dogs significantly reduces the amount of induction drug required for induction of anaesthesia.
Uporaba deksmedetomidina za pripravo na kirurške posege pri psih bistveno zmanjša količino indukcijskega zdravila, potrebnega za indukcijo anestezije.
All anaesthetic agents used for induction or maintenance of anaesthesia should be administered to effect.
Vse anestetike za induciranje ali vzdrževanje anestezije morate dajati, dokler ni dosežen učinek.
Dogs: After an intramuscular dose of 50 micrograms/kg a maximum concentration in plasma of about 12 nanograms/ml is reached after 0.6 hours.
Psi: Po intramuskularnem odmerku v višini 50 mikrogramov/kg je najvišja koncentracija v plazmi, približno 12 nanogramov/ml, dosežena po 0,6 ure.
Cats: After administration of 40 micrograms dexmedetomidine/ kg bw intramuscularly concurrently with 5 mg ketamine /kg bw to cats, the maximum concentration of dexmedetomidine increased twofold but there was no effect on T max.
Mačke: Po intramuskularni uporabi 40 mikrogramov deksmedetomidina/kg telesne teže skupaj s 5 mg ketamina/kg telesne teže se je najvišja koncentracija povečala dvakrat, vendar ni bilo učinka na Tmax.
When dexmedetomidine is used as a premedicant in cats, vomiting, retching, pale mucous membranes, and low body temperature may occur.
Pri uporabi deksmedetomidina za pripravo mačk lahko pride do bruhanja, poskusov bljuvanja, bledih mukoznih membran in nizke telesne temperature.
By virtue of its α2-adrenergic activity, dexmedetomidine causes decreases in heart rate and body temperature.
Deksmedetomidin zaradi α2-adrenergičnega delovanja povzroča znižanje srčnega utripa in telesne temperature.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION The product is intended for:
ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) IN NAČIN UPORABE IN
Dogs: After an intramuscular dose of 50 micrograms/kg a maximum concentration in plasma of about 12 ng/ml is reached after 0.6 hours.
Psi: Po intramuskularnem odmerku v višini 50 mikrogramov/kg je najvišja koncentracija v plazmi, približno 12 ng/ml, dosežena po 0,6 ure.
Dosing for cats is presented in the following table.
Naslednja tabela prikazuje odmerjanje za mačke.
Concomitant use of dexmedetomidine and butorphanol produces sedative and analgesic effects beginning no later than 15 minutes after administration.
Sočasna uporaba deksmedetomidina in butorfanola sproži sedativne in analgetične učinke v manj kot 15 minutah po dajanju zdravila.
Intramuscularly: up to 500 micrograms/square metre body surface area
Intramuskularno: do 500 mikrogramov/kvadratni meter telesne površine
A dose of 10 mg ketamine/ kg used concurrently with 40 micrograms dexmedetomidine/ kg may cause tachycardia.
Uporaba odmerka 10 mg ketamina/kg skupaj s 40 mikrogrami deksmedetomidina/kg lahko povzroči tahihardijo.
The corresponding doses based on body weight are presented in the following tables.
Tabela spodaj prikazuje ustrezne odmerke na osnovi telesne teže.
Package size: 10 ml, 10 x10 ml.
Velikost pakiranja: 10 ml, 10 x 10 ml
For information on adverse reactions, see section: Adverse Reactions.
Za dodatne informacije o neželenih učinkih glejte odsek Neželeni učinki.
6.5 Nature and composition of immediate packaging Cardboard box with 1 glass (Type I) vial of 20 ml (with filling volume of 15 ml) with a bromobutyl rubber stopper and aluminium cap.
Kartonska škatla z eno 20-mililitrsko vialo iz stekla tipa I (s polnilnim volumnom 15 ml) z gumijastim zamaškom iz bromobutilne gume in aluminijasto zaporko.
ROUTE(S) OF ADMINISTRATION Dogs: IM, IV
POT(I) UPORABE ZDRAVILA Psi: i.m., i.v.
Attention should be given during the administration of intravenous induction drugs to effect.
Med dajanjem intravenskega indukcijskega zdravila do doseženega učinka morate biti pozorni.
List of excipients:
Seznam pomožnih snovi: